Overview

Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention

Status:
Completed
Trial end date:
2017-06-19
Target enrollment:
Participant gender:
Summary
The primary objective of the study was to evaluate the effect of erenumab compared to placebo on the change from baseline in monthly migraine days.
Phase:
Phase 3
Details
Lead Sponsor:
Amgen
Treatments:
Erenumab